These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28210077)

  • 1. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
    Tighe D; McNamara D
    World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
    Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL; Sipponen T
    Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which patients with inflammatory bowel disease should receive combination therapy?
    Cross RK
    Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):715-7. PubMed ID: 25912620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
    Colman RJ; Rubin DT
    J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
    Lucas Ramos J; Suárez Ferrer C; Poza Cordón J; Sánchez Azofra M; Rueda García JL; Martin Arranz E; Yebra Carmona J; Andaluz García I; Martín Arranz MD
    Gastroenterol Hepatol; 2021 May; 44(5):337-345. PubMed ID: 33272733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
    Cheon JH
    J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
    Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
    Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
    Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
    PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.